Vimarsana
Biggest News Aggregation in the World

Fred Ledley News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fred Ledley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fred Ledley Today - Breaking & Trending Today

Biden Administration Releases Policy To Seize Drug Patents Based On Price - Vimarsana News

Biden Administration Releases Policy To Seize Drug Patents Based On Price

The Biden team has released a plan for federal officials to use "march-in rights" to seize the patents of drugs they deem overpriced.

US universities short-changed on research | Times Higher Education (THE) - Vimarsana News

US universities short-changed on research | Times Higher Education (THE)

Companies consistently don’t pay full value for medical discoveries in what Bentley study calls a ‘systematic problem’

Pharmaceutical industry could experience no impact to innovation under H.R. 3 - Vimarsana News

Pharmaceutical industry could experience no impact to innovation under H.R. 3

WASHINGTON, D.C. and WALTHAM, MA – August 12, 2021 — A new analysis of publicly reported financial information of the pharmaceutical industry finds...

COVID-19 vaccine development built on >$17 billion in NIH funding for vaccine technologies - Vimarsana News

COVID-19 vaccine development built on >$17 billion in NIH funding for vaccine technologies

Credit: © Center for Integration of Science and Industry at Bentley University The unprecedented development of COVID-19 vaccines less than a year after discovery of this virus was enabled by more than $17 billion of research on vaccine technologies funded by the NIH prior to the pandemic, according to new research from Bentley University'sCenter for Integration of Science and Industry. The article, titled "NIH funding for vaccine readiness before the COVID-19 pandemic," demonstrates the critical role this broad foundation of government-funded research plays in ensuring vaccine readiness. Th...

Investment risk & return from emerging public biotech companies comparable to non-biotech - Vimarsana News

Investment risk & return from emerging public biotech companies comparable to non-biotech

 E-Mail IMAGE: Shareholder value at the end of 2016 compared to IPO for biotech companies and paired controls completing IPOs 1997-2016. Net growth in shareholder value, and the fraction of companies generating... view more  Credit: Center for Integration of Science and Industry, Bentley University Investing in biotech companies may not entail higher risk than investing in other sectors, according to a new report from Bentley University's Center for Integration of Science and Industry. A large scale study of biotechnology companies that completed Initial Public Offerings (IPOs) from...